Form 4: BeOne Medicines GC Exercises Options, Sells ADSs

BeOne Medicines' SVP and General Counsel, Chan Henry Lee, exercised stock options and sold American Depositary Shares under a pre-arranged trading plan.

Summary

• SVP, General Counsel Chan Henry Lee engaged in transactions on March 11, 2026, involving both derivative and non-derivative securities of BeOne Medicines Ltd.
• Exercised options to acquire a total of 341 American Depositary Shares (ADSs) at varying prices: 110 ADSs at $194.47, 133 ADSs at $213.32, and 98 ADSs at $159.03.
• Immediately sold all 341 ADSs acquired through the exercise at a price of $300 per ADS.
• Exercised options for 1,430 Ordinary Shares at an exercise price of $14.96, 1,729 Ordinary Shares at $16.41, and 1,274 Ordinary Shares at $12.23.
• Following these transactions, the reporting person beneficially owns 22,490 Ordinary Shares from the first option grant, 86,684 Ordinary Shares from the second, and 110,396 Ordinary Shares from the third.
• The sale of ADSs was conducted pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.
• Each American Depositary Share represents 13 Ordinary Shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's profit-taking on ADSs, the significant retention of exercised options at low strike prices indicates continued long-term alignment with shareholder interests.

Positives

• The sale of American Depositary Shares (ADSs) at $300 per share, after exercising options at lower prices ($194.47, $213.32, $159.03), indicates a profitable transaction for the reporting person.
• The exercise of options for Ordinary Shares at significantly lower strike prices ($14.96, $16.41, $12.23) suggests potential future value and management confidence in the company's long-term prospects, as these options are retained.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned activity and reducing concerns about opportunistic trading based on non-public information.

Negatives

• The immediate sale of all 341 American Depositary Shares (ADSs) acquired through option exercise could be interpreted as the reporting person taking profits rather than increasing their direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common for executives managing their equity compensation. While the sale of ADSs represents profit-taking, the continued holding of a substantial number of exercised options at much lower strike prices suggests a long-term vested interest in BeOne Medicines' performance, aligning with typical executive compensation strategies in the biotech or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The sale of ADSs by a senior executive could be viewed as a minor signal of profit-taking, but the pre-planned nature and retention of other options mitigate negative interpretations. The exercise of options at low prices suggests potential future value for the company's stock.

Key Dates

Recommendation

The filing details routine insider transactions by a senior executive, including exercising options and selling a portion of the acquired shares under a pre-arranged 10b5-1 plan. While the executive took profits on some American Depositary Shares, they also exercised and retained a substantial number of ordinary share options at significantly lower strike prices, indicating continued long-term alignment with the company's performance. This type of transaction is generally expected and does not provide a strong signal for a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate as it reflects a neutral to slightly positive outlook without significant new information to alter an existing investment thesis.

Keywords

BeOne Medicines, ONC, SEC Form 4, Insider Trading, Stock Options, American Depositary Shares, Rule 10b5-1, Executive Compensation, Chan Henry Lee